Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Dan T. Vogl, Yulia Nefedova, E. Paul Wileyto, Chau Nguyen, Cynthia Diaczynsky, Inna Strakovsky, Eva Bondesson, Helen Tuvesson, Erik Vahtola, Adam D. Cohen, Sandra Susanibar-Adaniya, Adam Waxman, Shivani Kapur, Alfred L. Garfall, Edward A. Stadtmauer

Blood (2024) 144 (Supplement 1): 7060.

https://doi.org/10.1182/blood-2024-204155

Published: 2024

Journal Articles

A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma

Dan T. Vogl, MD, Yulia Nefedova, MD PhD, E. Paul Wileyto, PhD, Harjeet Sembhi, Inna Strakovsky, MPH, MRA, Chau Nguyen, Rimzim Taneja, Eva Bondesson, PhD, Helena Eriksson, PhD, Helen Tuvesson, PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-137482

Published: 2020

Journal Articles

A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma

Indu R Ramachandran, PhD, Cindy Lin, PhD, Tess Chase, Dmitry Gabrilovich, MD PhD, Yulia Nefedova, MD PhD

Blood (2014) 124 (21): 5729.

https://doi.org/10.1182/blood.V124.21.5729.5729

Published: 2014

Journal Articles

Inhibition of Wnt/ß-Catenin Pathway with ICG-001 Induces Apoptosis in Multiple Myeloma.

Eileen R Grigson, MS, Alexandra Pisklakova, MD, Brittany Weissman, Yulia Nefedova, MD, PhD

Blood (2012) 120 (21): 2951.

https://doi.org/10.1182/blood.V120.21.2951.2951

Published: 2012

Journal Articles

Accumulation of Myeloid-Derived Suppressor Cells in Bone Marrow in Multiple Myeloma Induces Tumor-Specific Immune Suppression and Promotes Tumor Growth

Indu R Ramachandran, PhD, Anna Martner, PhD, Thomas C Condamine, PhD, Alexandra Pisklakova, MD, Tess Chase, Dmitry Gabrilovich, MD, PhD, Yulia Nefedova, MD, PhD

Blood (2012) 120 (21): 3954.

https://doi.org/10.1182/blood.V120.21.3954.3954

Published: 2012

Journal Articles

Influence of Targeted Therapy in Redefining High-Risk Myeloma.

Lori Hazlehurst, PhD, William S. Dalton, MD, PhD, Danielle Yarde, Yulia Nefedova, MD, PhD, Dmitry Gabrilovich

Blood (2008) 112 (11): sci-7.

https://doi.org/10.1182/blood.V112.11.sci-7.sci-7

Published: 2008

Journal Articles

Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy

Yulia Nefedova, Daniel M. Sullivan, Sophia C. Bolick, William S. Dalton, Dmitry I. Gabrilovich

Blood (2008) 111 (4): 2220–2229.

https://doi.org/10.1182/blood-2007-07-102632

Published: 2008

Journal Articles

A New Target in Multiple Myeloma: Inhibition of Notch Pathway Induces Apoptosis and Enhances Drug Sensitivity of Myeloma Cells In Vitro and In Vivo.

Yulia Nefedova, MD, PhD, Krista Verali, Daniel M. Sullivan, MD, William S. Dalton, MD, PhD, Dmitry I. Gabrilovich, MD, PhD

Blood (2006) 108 (11): 841.

https://doi.org/10.1182/blood.V108.11.841.841

Published: 2006

Journal Articles

Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands

Pingyan Cheng, Yulia Nefedova, Cesar A. Corzo, Dmitry I. Gabrilovich

Blood (2006) 109 (2): 507–515.

https://doi.org/10.1182/blood-2006-05-025601

Published: 2006

Includes: Supplemental data

Journal Articles

Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines

Yulia Nefedova, Pingyan Cheng, Melissa Alsina, William S. Dalton, Dmitry I. Gabrilovich

Blood (2004) 103 (9): 3503–3510.

https://doi.org/10.1182/blood-2003-07-2340

Published: 2004

Journal Articles

Notch signaling is necessary but not sufficient for differentiation of dendritic cells

Pingyan Cheng, Yulia Nefedova, Lucio Miele, Barbara A. Osborne, Dmitry Gabrilovich

Blood (2003) 102 (12): 3980–3988.

https://doi.org/10.1182/blood-2003-04-1034

Published: 2003

NARROW

Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma

A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma

A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma

Inhibition of Wnt/ß-Catenin Pathway with ICG-001 Induces Apoptosis in Multiple Myeloma.

Accumulation of Myeloid-Derived Suppressor Cells in Bone Marrow in Multiple Myeloma Induces Tumor-Specific Immune Suppression and Promotes Tumor Growth

Influence of Targeted Therapy in Redefining High-Risk Myeloma.

Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy

A New Target in Multiple Myeloma: Inhibition of Notch Pathway Induces Apoptosis and Enhances Drug Sensitivity of Myeloma Cells In Vitro and In Vivo.

Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands

Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines

Notch signaling is necessary but not sufficient for differentiation of dendritic cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only